相似文献
1
Hepatitis C viral kinetics: the past, present, and future.
Clin Liver Dis. 2013 Feb;17(1):13-26. doi: 10.1016/j.cld.2012.09.003.
2
Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128).
Hepatology. 2012 Apr;55(4):1030-7. doi: 10.1002/hep.24788. Epub 2012 Feb 15.
3
Silymarin for HCV infection.
Antivir Ther. 2013;18(2):141-7. doi: 10.3851/IMP2402. Epub 2012 Sep 25.
4
Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?
Antivir Ther. 2012;17(6 Pt B):1171-82. doi: 10.3851/IMP2428. Epub 2012 Oct 5.
5
Excitement grows for potential revolution in hepatitis C virus treatment.
Nat Rev Drug Discov. 2010 Jul;9(7):501-3. doi: 10.1038/nrd3214.
6
Meet the Classes of Directly Acting Antiviral Agents: Strengths and Weaknesses.
Clin Liver Dis. 2015 Nov;19(4):605-17, v. doi: 10.1016/j.cld.2015.06.002. Epub 2015 Jul 26.
7
HCV RNA viral load assessments in the era of direct-acting antivirals.
Am J Gastroenterol. 2013 Apr;108(4):471-5. doi: 10.1038/ajg.2012.248.
8
Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors.
J Viral Hepat. 2011 May;18(5):338-48. doi: 10.1111/j.1365-2893.2010.01314.x.
9
[Hepatitis C virus: therapeutic targets and new drugs].
Vopr Virusol. 2012 Sep-Oct;57(5):10-5.
10
Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
J Theor Biol. 2010 Dec 7;267(3):330-40. doi: 10.1016/j.jtbi.2010.08.036. Epub 2010 Sep 8.
引用本文的文献
1
Revisiting Acyclovir Dosing for Adult Viral Encephalitis Using a Full Bayesian LeiCNS PBPK Modeling Approach.
Clin Pharmacokinet. 2025 Jul 13. doi: 10.1007/s40262-025-01545-w.
2
Efficacy of 8-week daclatasvir-sofosbuvir regimen in chronic hepatitis C: a systematic review and meta-analysis.
Virol J. 2024 Nov 4;21(1):275. doi: 10.1186/s12985-024-02544-2.
3
Conformational dynamics of the hepatitis C virus 3'X RNA.
RNA. 2024 Aug 16;30(9):1151-1163. doi: 10.1261/rna.079983.124.
4
Classifying hepatitis B therapies with insights from covalently closed circular DNA dynamics.
Virol Sin. 2024 Feb;39(1):9-23. doi: 10.1016/j.virs.2023.12.005. Epub 2023 Dec 16.
5
Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.
Clin Pharmacol Ther. 2021 Apr;109(4):867-891. doi: 10.1002/cpt.2198. Epub 2021 Mar 9.
6
Intracellular Hepatitis C Virus Modeling Predicts Infection Dynamics and Viral Protein Mechanisms.
J Virol. 2018 May 14;92(11). doi: 10.1128/JVI.02098-17. Print 2018 Jun 1.
7
Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b.
World J Gastroenterol. 2017 Apr 7;23(13):2355-2364. doi: 10.3748/wjg.v23.i13.2355.
8
Oxidized Low-Density Lipoprotein Is a Novel Predictor of Interferon Responsiveness in Chronic Hepatitis C Infection.
Cell Mol Gastroenterol Hepatol. 2015 Mar 14;1(3):285-294.e1. doi: 10.1016/j.jcmgh.2015.03.002. eCollection 2015 May.
9
Border Control in Hepatitis C Virus Infection: Inhibiting Viral Entry.
ACS Infect Dis. 2015 Sep 11;1(9):416-9. doi: 10.1021/acsinfecdis.5b00060. Epub 2015 Aug 11.
10
Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients.
Can J Gastroenterol Hepatol. 2016;2016:2872371. doi: 10.1155/2016/2872371. Epub 2016 Apr 11.
本文引用的文献
1
Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate.
PLoS Pathog. 2012;8(8):e1002881. doi: 10.1371/journal.ppat.1002881. Epub 2012 Aug 23.
2
The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin.
J Viral Hepat. 2012 Jul;19(7):488-96. doi: 10.1111/j.1365-2893.2011.01569.x. Epub 2011 Dec 22.
3
Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor.
Bull Math Biol. 2012 Aug;74(8):1789-817. doi: 10.1007/s11538-012-9736-y. Epub 2012 May 26.
4
Pharmacokinetic/Pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors.
Antimicrob Agents Chemother. 2012 Jun;56(6):3144-56. doi: 10.1128/AAC.06283-11. Epub 2012 Apr 2.
5
Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin.
J Hepatol. 2012 Jul;57(1):39-46. doi: 10.1016/j.jhep.2012.02.015. Epub 2012 Mar 10.
6
Understanding silibinin's modes of action against HCV using viral kinetic modeling.
J Hepatol. 2012 May;56(5):1019-1024. doi: 10.1016/j.jhep.2011.12.012. Epub 2012 Jan 13.
7
Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B.
Curr Hepat Rep. 2011 Jul 2;10(3):214-227. doi: 10.1007/s11901-011-0101-7.
8
Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128).
Hepatology. 2012 Apr;55(4):1030-7. doi: 10.1002/hep.24788. Epub 2012 Feb 15.
9
Second-wave protease inhibitors: choosing an heir.
Clin Liver Dis. 2011 Aug;15(3):597-609. doi: 10.1016/j.cld.2011.05.014. Epub 2011 Jun 25.
10
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1.
Hepatology. 2011 Dec;54(6):1956-65. doi: 10.1002/hep.24609.
Zotero 插件